Trifluperidol
From Wikipedia, the free encyclopedia
Trifluperidol
|
|
Systematic (IUPAC) name | |
1-(4-fluorophenyl)-4-[4-hydroxy-4-[3-(trifluoromethyl)phenyl]-1-piperidyl]butan-1-one | |
Identifiers | |
CAS number | |
ATC code | N05 |
PubChem | |
Chemical data | |
Formula | C22H23F4NO2 |
Mol. mass | 409.417 g/mol |
Pharmacokinetic data | |
Bioavailability | ? |
Metabolism | ? |
Half life | ? |
Excretion | ? |
Therapeutic considerations | |
Pregnancy cat. |
? |
Legal status | |
Routes | Oral |
Trifluperidol is a drug which is a butyrophenone derivative. It has general properties similar to those of haloperidol, but is considerably more potent by weight, and causes relatively more severe side effects, especially tardive dyskinesia and other extrapyramidal effects. It is used in the treatment of psychoses including mania and schizophrenia.
Trifluperidol was discovered at Janssen Pharmaceutica in 1959.
[edit] References
- Gallant DM, Bishop MP, Timmons E, Steele CA, A controlled evaluation of Trifluperidol: a new potent psychopharmacologic agent, Curr Ther Res Clin Exp. 1963 Sep;27:463-71.
- Gallant DM, Bishop MP, Timmons E, Steele CA, Trifluperidol: a butyrophenone derivative, Am J Psychiatry. 1963 Nov;120:485-7.
|